
Akebia Therapeutics, Inc.: updates and filings
Price
$0.42
November 19, 2026Market cap $113M
What Ploutos Investor adds for Akebia Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 12 fiscal years, from 2014
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Material agreement entered, material agreement ended, new material financial obligation, unregistered sale of shares, Regulation FD disclosure, other material eventsForm8-K
- Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operationsForm8-K
- Oct 23, 2026Delisting noticeForm8-K
- Oct 14, 2026Officer or director changeForm8-K
- Aug 5, 2026Shares registered for employeesFormS-8
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jun 30, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 22, 2026Shareholder voteForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 15, 2026Preliminary proxy statementFormPRE 14A
- Apr 1, 2026Officer or director changeForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Feb 9, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jan 30, 2026Material agreement entered, new material financial obligation, officer or director changeForm8-K
- Jan 21, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 12, 2026Results of operations, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation, unregistered sale of shares, Regulation FD disclosure, other material events | Document |
| Nov 5, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations | Document |
| Oct 23, 2026 | 8-K | Delisting notice | Document |
| Oct 14, 2026 | 8-K | Officer or director change | Document |
| Aug 5, 2026 | S-8 | Shares registered for employees | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jun 30, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 22, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 15, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 1, 2026 | 8-K | Officer or director change | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Feb 9, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jan 30, 2026 | 8-K | Material agreement entered, new material financial obligation, officer or director change | Document |
| Jan 21, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 8, 2011.
The full analysis
What do Akebia Therapeutics's filings show?
The filings are where every one of Akebia Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.